Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure.
Growth hormone-releasing hormone attenuates cardiac hypertrophy and improves heart function in pressure overload-induced heart failure.
复制标题
DOI:
10.1073/pnas.1712612114
复制
发表时间:
2017-11-07
影响因子:
11.1
通讯作者:
Granata R
中科院分区:
文献类型:
--
作者:
Gesmundo I;Miragoli M;Carullo P;Trovato L;Larcher V;Di Pasquale E;Brancaccio M;Mazzola M;Villanova T;Sorge M;Taliano M;Gallo MP;Alloatti G;Penna C;Hare JM;Ghigo E;Schally AV;Condorelli G;Granata R
Pathological cardiac hypertrophy, characterized by heart growth in response to pressure or volume overload, such as in the setting of hypertension, is the main risk factor for heart failure (HF). The identification of therapeutic strategies to prevent or reverse cardiac hypertrophy is therefore a priority for curing HF. It is known that growth hormone-releasing hormone (GHRH) displays cardioprotective functions; however, its therapeutic potential in hypertrophy and HF is unknown. Here we show that GHRH reduces cardiomyocyte hypertrophy in vitro through inhibition of hypertrophic pathways. In vivo, the GHRH analog MR-409 attenuates cardiac hypertrophy in mice subjected to transverse aortic constriction and improves cardiac function. These findings suggest therapeutic use of GHRH analogs for treatment of pathological cardiac hypertrophy and HF. It has been shown that growth hormone-releasing hormone (GHRH) reduces cardiomyocyte (CM) apoptosis, prevents ischemia/reperfusion injury, and improves cardiac function in ischemic rat hearts. However, it is still not known whether GHRH would be beneficial for life-threatening pathological conditions, like cardiac hypertrophy and heart failure (HF). Thus, we tested the myocardial therapeutic potential of GHRH stimulation in vitro and in vivo, using GHRH or its agonistic analog MR-409. We show that in vitro, GHRH(1-44)NH2 attenuates phenylephrine-induced hypertrophy in H9c2 cardiac cells, adult rat ventricular myocytes, and human induced pluripotent stem cell-derived CMs, decreasing expression of hypertrophic genes and regulating hypertrophic pathways. Underlying mechanisms included blockade of Gq signaling and its downstream components phospholipase Cβ, protein kinase Cε, calcineurin, and phospholamban. The receptor-dependent effects of GHRH also involved activation of Gαs and cAMP/PKA, and inhibition of increase in exchange protein directly activated by cAMP1 (Epac1). In vivo, MR-409 mitigated cardiac hypertrophy in mice subjected to transverse aortic constriction and improved cardiac function. Moreover, CMs isolated from transverse aortic constriction mice treated with MR-409 showed improved contractility and reversal of sarcolemmal structure. Overall, these results identify GHRH as an antihypertrophic regulator, underlying its therapeutic potential for HF, and suggest possible beneficial use of its analogs for treatment of pathological cardiac hypertrophy.
登录
查看更多内容
DOI:
10.1038/nrm3495
发表时间:
2013-01
期刊:
Nature reviews. Molecular cell biology
影响因子:
--
作者:
通讯作者:
--
影响因子:
10.8
作者:
Granata, Riccarda;Trovato, Letizia;Ghigo, Ezio
通讯作者:
Ghigo, Ezio
影响因子:
5
作者:
Markou, T;Hadzopoulou-Cladaras, M;Lazou, A
通讯作者:
Lazou, A
影响因子:
20.1
作者:
Metrich, Melanie;Lucas, Alexandre;Lezoualc'h, Frank
通讯作者:
Lezoualc'h, Frank
影响因子:
4.8
作者:
Christensen, AE;Selheim, F;Doskeland, SO
通讯作者:
Doskeland, SO